MetaVia Inc
MTVA1.040USD
+0.123+13.38%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
25.16MMarket Cap
LossP/E TTM
More Details of MetaVia Inc Company
MetaVia Inc., formerly NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus resulting in body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, GLP-1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
Company Info
Ticker SymbolMTVA
Company nameMetaVia Inc
IPO dateAug 05, 2016
CEOMr. Hyung Heon Kim
Number of employees9
Security typeOrdinary Share
Fiscal year-endAug 05
Address545 Concord Avenue
CityCAMBRIDGE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02138
Phone18577029600
Websitehttps://metaviatx.com/
Ticker SymbolMTVA
IPO dateAug 05, 2016
CEOMr. Hyung Heon Kim
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Hyung Heon Kim
Mr. Hyung Heon Kim
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
57.75K
+20.35%
Mr. Andrew Ian Koven
Mr. Andrew Ian Koven
Independent Chairman of the Board
Independent Chairman of the Board
42.97K
+339.90%
Mr. Jason L. Groves, Esq., J.D.
Mr. Jason L. Groves, Esq., J.D.
Independent Director
Independent Director
42.97K
+339.90%
Mr. Michael Salsbury
Mr. Michael Salsbury
Independent Director
Independent Director
42.97K
+339.90%
Mr. Mark A. Glickman
Mr. Mark A. Glickman
Independent Director
Independent Director
37.10K
+849.71%
Mr. Marshall H. Woodworth
Mr. Marshall H. Woodworth
Chief Financial Officer
Chief Financial Officer
6.63K
-68.16%
Dr. James Patrick (Jim) Tursi, M.D.
Dr. James Patrick (Jim) Tursi, M.D.
Independent Director
Independent Director
--
--
Mr. D. Gordon Strickland
Mr. D. Gordon Strickland
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Hyung Heon Kim
Mr. Hyung Heon Kim
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
57.75K
+20.35%
Mr. Andrew Ian Koven
Mr. Andrew Ian Koven
Independent Chairman of the Board
Independent Chairman of the Board
42.97K
+339.90%
Mr. Jason L. Groves, Esq., J.D.
Mr. Jason L. Groves, Esq., J.D.
Independent Director
Independent Director
42.97K
+339.90%
Mr. Michael Salsbury
Mr. Michael Salsbury
Independent Director
Independent Director
42.97K
+339.90%
Mr. Mark A. Glickman
Mr. Mark A. Glickman
Independent Director
Independent Director
37.10K
+849.71%
Mr. Marshall H. Woodworth
Mr. Marshall H. Woodworth
Chief Financial Officer
Chief Financial Officer
6.63K
-68.16%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dong-A ST Co., Ltd.
61.27%
The Vanguard Group, Inc.
0.26%
UBS Financial Services, Inc.
0.24%
Kim (Hyung Heon)
0.24%
Koven (Andrew Ian)
0.18%
Other
37.80%
Shareholders
Shareholders
Proportion
Dong-A ST Co., Ltd.
61.27%
The Vanguard Group, Inc.
0.26%
UBS Financial Services, Inc.
0.24%
Kim (Hyung Heon)
0.24%
Koven (Andrew Ian)
0.18%
Other
37.80%
Shareholder Types
Shareholders
Proportion
Corporation
61.27%
Individual Investor
1.28%
Investment Advisor
0.57%
Investment Advisor/Hedge Fund
0.27%
Research Firm
0.17%
Venture Capital
0.07%
Hedge Fund
0.02%
Other
36.34%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
39
15.87M
65.59%
+4.69M
2025Q1
40
6.18M
66.88%
-362.61K
2024Q4
48
6.53M
78.71%
-206.27K
2024Q3
44
6.72M
80.64%
+31.88K
2024Q2
51
6.49M
81.55%
+3.23M
2024Q1
54
3.12M
64.62%
+1.15M
2023Q4
53
1.92M
74.31%
+1.65M
2023Q3
54
1.93M
74.71%
+1.67M
2023Q2
60
1.75M
73.99%
+1.49M
2023Q1
85
1.75M
74.89%
+1.48M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dong-A ST Co., Ltd.
14.83M
75.69%
+4.83M
+48.34%
Jun 09, 2025
The Vanguard Group, Inc.
63.58K
0.32%
+3.13K
+5.18%
Mar 31, 2025
UBS Financial Services, Inc.
5.30K
0.03%
+3.98K
+302.05%
Mar 31, 2025
Kim (Hyung Heon)
57.75K
0.29%
+9.77K
+20.35%
Jun 09, 2025
Koven (Andrew Ian)
42.97K
0.22%
+33.20K
+339.90%
Jun 30, 2025
Groves (Jason L)
42.97K
0.22%
+33.20K
+339.90%
Jun 30, 2025
Strickland (D Gordon)
42.96K
0.22%
+33.20K
+339.93%
Jun 30, 2025
Salsbury (Michael)
42.97K
0.22%
+33.20K
+339.90%
Jun 30, 2025
SG Americas Securities, L.L.C.
41.00K
0.21%
-61.00
-0.15%
Mar 31, 2025
Glickman (Mark A)
37.10K
0.19%
+33.20K
+849.71%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Sep 12, 2022
Merger
30→1
Sep 12, 2022
Merger
30→1
Date
Type
Ratio
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Aug 08, 2023
Merger
8→1
Sep 12, 2022
Merger
30→1
Sep 12, 2022
Merger
30→1
Sep 12, 2022
Merger
30→1
Sep 12, 2022
Merger
30→1
